New combo therapy tackles tough tumors
NCT ID NCT03486301
First seen Nov 12, 2025 · Last updated May 23, 2026 · Updated 36 times
Summary
This early-phase study tested an experimental drug called BDB001, given alone or with another cancer drug (pembrolizumab), in 87 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atlantic Health
Morristown, New Jersey, 07960, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34230, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.